Insilico Medicine (ISPC)

Insilico Medicine (ISPC)

Price: 2.68

Company and Business Model

Insilico Medicine is a biotechnology company focused on drug discovery and development using artificial intelligence. Its core products include AI-driven platforms for target identification, drug design, and preclinical development. The company operates primarily in the healthcare sector, with major revenue sources stemming from partnerships, collaborations, and research grants aimed at advancing therapeutic solutions for various diseases.

Investment Profile

The investment profile of Insilico Medicine is more aligned with growth investors due to its focus on innovative technologies and potential for future revenue generation. However, the high volatility and significant risks associated with its operations may not appeal to conservative investors. The stock may be suitable for those with a medium to long-term investment horizon, seeking exposure to the biotech sector.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-326.00 Risk
Revenue QoQ — quarter-over-quarter revenue growth
201.4%
EPS surprise
84.5% better than expected
20d volatility
4.7% stable
FMP / FinFeed data updated: 2026-06-09
Reco: Sell Potential: 30 Risk: 85 Updated: 2026-06-11 05:21
How recommendation works
Why AI thinks so:
High volatility and negative momentum raise significant concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-03 02:44 Hold Sell High volatility and negative momentum raise significant concerns.
2026-05-16 02:53 Sell Hold High volatility and negative fundamentals raise concerns.
2026-05-08 15:31 Sell scenario_deterioration
Insilico Medicine (ISPC) Eli Lilly

Фармацевтический гигант Eli Lilly (LLY) заключил сделку на $2.75 миллиарда с Insilico Medicine для вывода на рынок препаратов, разработанных с помощью ИИ

Американская фармацевтическая компания Eli Lilly заключила сделку на сумму $2.75 миллиарда с гонконгской Insilico Medicine для вывода на глобальный рынок лекарств, разработанных с использованием искусственного интеллекта.